ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 14, 2025
Dividend Increases/Decreases for the Week of February 14
Let's take a look at firms raising/lowering their dividends this week.
Feb 11, 2025
Vertex Pharma Is One of Our Favorite Biotechs
Image: Vertex Pharma has performed quite well since the beginning of 2023. Looking to 2025, Vertex expects total revenue of $11.75-$12 billion, which includes expectations for continued growth in its cystic fibrosis portfolio, “including the U.S. launch of ALYFTREK, as well as continued uptake of CASGEVY in multiple regions; and early contributions from the launch of JOURNAVX." Cash and total marketable securities as of the end of last year were $11.2 billion, compared to $13.7 billion at the end of 2023 due to the cash consideration paid to acquire Alpine and share buybacks. Vertex had no traditional debt. We continue to like Vertex Pharma as a holding in the Best Ideas Newsletter portfolio.
Feb 7, 2025
Dividend Increases/Decreases for the Week of February 7
Let's take a look at firms raising/lowering their dividends this week.
Feb 6, 2025
Chipotle's Long-term Growth Prospects Are Impressive
Image Source: Valuentum. During the fourth quarter of 2024, Chipotle bought back ~$330 million of stock, and as of the end of last year, the company had $1 billion remaining available under share repurchase authorizations. Looking to 2025, management expects full year comparable restaurant sales growth in the low to mid-single digit range and plans for 315-345 new company-owned restaurant openings with over 80% having a Chipotlane. At the end of 2024, Chipotle had 3,746 total restaurants, and the firm is targeting as many as 7,000 restaurants in North America alone. We like Chipotle’s long-term growth potential, and the firm remains a holding in the Best Ideas Newsletter portfolio.
Feb 4, 2025
Tesla Remains a Net Cash Rich, Free Cash Flow Generating Powerhouse
Image: Tesla continues to attack costs with average cost of goods sold per vehicle reaching an all-time low in the fourth quarter of 2024. Image Source: Tesla. In the fourth quarter, Model 3/Y production fell 8% on a year-over-year basis, while other models production advanced 25%. Model 3/Y deliveries increased 2%, while other models deliveries advanced 3%. Tesla’s quarterly net cash provided by operating activities increased 10%, to $4.8 billion, while capital spending increased 21%, to $2.8 billion, resulting in free cash flow of $2.03 billion, down 2% on a year-over-year basis. Free cash flow for the full year 2024 was $3.58 billion, down 18% on a year-over-year basis. Tesla ended the calendar year with $36.6 billion in cash, cash equivalents and investments. Though free cash flow faced pressure during 2024, the company remains a net cash rich, free-cash-flow generating powerhouse.
Feb 1, 2025
ASML Holding’s Bookings Soar in Fourth Quarter
Image Source: TradingView. We continue to like ASML as an idea in the ESG Newsletter portfolio, and the company’s bookings number for the fourth quarter was solid, helping to alleviate some concerns that arose by its weak third-quarter bookings result. The company’s first-quarter outlook for net sales came in ahead of what the Street was looking for, and we liked that ASML reiterated its total net sales expectation for 2025 to be between €30 billion and €35 billion.
Jan 31, 2025
Apple Reports Best Quarter Ever Despite Declining iPhone, China Sales
Image Source: TradingView. During the quarter, Apple returned to shareholders $3.9 billion in dividends and equivalents and $23.3 billion in share repurchases. Looking to the March quarter, management expects total company revenue to grow low to mid-single-digits year-over-year, with Services revenue to grow low double-digits year-over-year. It expects its gross margin to be between 46.5%-47.5%, about in line with the December quarter. We continue to be fans of Apple’s large installed base (2.35 billion active devices) and growing, high-margin Services business, and the company remains a key holding in the newsletter portfolios.
Jan 31, 2025
Dividend Increases/Decreases for the Week of January 31
Let's take a look at firms raising/lowering their dividends this week.
Jan 23, 2025
Procter & Gamble on Track to Deliver on Fiscal Year Guidance
Image Source: Procter & Gamble. Looking to fiscal 2025 guidance, all-in sales growth is expected in the range of 2%-4% versus the prior year. Organic growth for the fiscal year is targeted in the range of 3%-5%. P&G reiterated its core earnings per share growth for the fiscal year to be in the range of 5%-7%, equating to a range of $6.91-$7.05, or a 6% increase at the midpoint. In fiscal 2025, P&G expects to pay around $10 billion in dividends and repurchase $6-$7 billion of common shares. At the time of this writing, shares of P&G yield ~2.5%.
Jan 23, 2025
Kinder Morgan Is Now Covering Cash Dividends Paid with Free Cash Flow
Image: Kinder Morgan’s shares have been on a tear after the midstream energy giant reports healthier free cash flow that covers cash dividends paid.Kinder Morgan is doing a much better job covering dividends with traditional free cash flow these days. For the three months ended December 31, 2024, cash flow from operations was $1.51 billion, with capital expenditures coming in at $772 million, resulting in free cash flow of $738 million, which was in excess of the company’s cash dividends paid of $642 million in the quarter. For the year ended December 31, 2024, free cash flow was $3 billion, which was in excess of cash dividends paid of $2.6 billion, resulting in free cash flow after cash dividends paid of $449 million.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.